Biogen Reports final analysis Data for Palbociclib in Atrial fibrillation

Biogen today announced final analysis results for Palbociclib in patients with Atrial fibrillation. The study demonstrated that Palbociclib improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Atrial fibrillation and support the continued development of Palbociclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Palbociclib was consistent with previous observations, with no new safety signals identified.